Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry.

Date publication

novembre 2022

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Pr COUTANT Charles , Dr DABAKUYO-YONLI Sandrine , Dr LADOIRE Sylvain , Dr PEIGNAUX Karine , Dr DESMOULINS Isabelle , Dr ROUFFIAC-THOUANT Magali

Tous les auteurs :
Kada Mohammed S, Dabakuyo Yonli TS, Desmoulins I, Manguem Kamga A, Jankowski C, Padeano MM, Loustalot C, Costaz H, Causeret S, Peignaux K, Rouffiac M, Coutant C, Arnould L, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36417042

Résumé

The prognosis of local invasive recurrence (LIR) after prior carcinoma in situ (CIS) of the breast has not been widely studied and existing data are conflicting, especially considering the specific prognosis of this entity, compared to de novo invasive breast cancer (de novo IBC) and with LIR after primary IBC.

Mots clés

Breast cancer, DCIS, Ductal carcinoma in situ, Local invasive recurrence, Survival, Systemic adjuvant therapies

Référence

Breast Cancer Res Treat. 2022 11 23;: